Top Markets
Coin of the day
OptiNose, Inc. OptiNose, Inc.

OptiNose, Inc.

OPTN
주식 순위 #9145
OptiNose, Inc. is a specialized pharmaceutical company primarily focused on... OptiNose, Inc. is a specialized pharmaceutical company primarily focused on innovating and bringing to market treatments for individuals under the care of ear, nose, throat, and allergy specialists throughout the United States. Its flagship product, XHANCE, utilizes the company's proprietary exhalation delivery system (EDS) to administer a topically-acting corticosteroid. This therapy is approved for treating chronic rhinosinusitis when accompanied by nasal polyps and is currently undergoing Phase IIIb clinical trials for broader chronic sinusitis treatment. The company also offers Onzetra Xsail, a powder-based EDS device, which is commercialized via a licensing agreement with Currax Pharmaceuticals LLC. Further expanding its pipeline, OptiNose is developing OPN-019, an investigational product that integrates a liquid EDS device with an antiseptic agent. Additionally, OptiNose has formed a partnership with Inexia Limited. This collaboration centers on the development, manufacturing, importation, and sale of products containing orexin receptor agonist or positive modulator molecules, intended for the treatment, diagnosis, or prevention of human conditions predominantly linked to orexin receptor activity. Established in 2000, OptiNose, Inc. operates from its corporate headquarters in Yardley, Pennsylvania.
주가
$9.60
마지막 동기화: 2025-05-21
시가총액
$1.08B
변동 (1일)
0.00%
변동 (1년)
0.00%
국가
US
거래 OptiNose, Inc. (OPTN)

카테고리

OptiNose, Inc. (OPTN)의 발행 주식 수
March 2025 기준 발행 주식 수: 11.67M
OptiNose, Inc.의 최신 재무 보고서와 주가에 따르면 현재 발행 주식 수는 11.67M입니다. December 2023 말 기준 회사는 112.08M주를 발행했습니다. 발행 주식 수는 일반적으로 주식 분할이나 자사주 매입에 의해 영향을 받습니다.
OptiNose, Inc. (OPTN)의 발행 주식 수 기록 (2015 ~ 2026)
매년 말 기준 발행 주식 수
연도 발행 주식 수 변화
2026 (TTM) 11.67M 14.88%
2024 10.16M -90.94%
2023 112.08M 1,857.16%
2022 5.73M -89.93%
2021 56.85M 17.77%
2020 48.28M 15.28%
2019 41.88M 5.31%
2018 39.77M 18.80%
2017 33.47M 1,131.11%
2016 2.72M -89.82%
2015 26.72M 0.00%
유사 기업 또는 경쟁사의 발행 주식 수